JP2020127430A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020127430A5 JP2020127430A5 JP2020085618A JP2020085618A JP2020127430A5 JP 2020127430 A5 JP2020127430 A5 JP 2020127430A5 JP 2020085618 A JP2020085618 A JP 2020085618A JP 2020085618 A JP2020085618 A JP 2020085618A JP 2020127430 A5 JP2020127430 A5 JP 2020127430A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- myostatin
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022130847A JP2022166238A (ja) | 2014-11-06 | 2022-08-19 | 抗プロ／潜在型－ミオスタチン抗体およびその使用 |
| JP2024077058A JP2024109663A (ja) | 2014-11-06 | 2024-05-10 | 抗プロ／潜在型－ミオスタチン抗体およびその使用 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076230P | 2014-11-06 | 2014-11-06 | |
| US62/076,230 | 2014-11-06 | ||
| US201562100361P | 2015-01-06 | 2015-01-06 | |
| US62/100,361 | 2015-01-06 | ||
| US201562187348P | 2015-07-01 | 2015-07-01 | |
| US62/187,348 | 2015-07-01 | ||
| US201562219094P | 2015-09-15 | 2015-09-15 | |
| US62/219,094 | 2015-09-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523975A Division JP6706617B2 (ja) | 2014-11-06 | 2015-11-06 | 抗プロ／潜在型−ミオスタチン抗体およびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130847A Division JP2022166238A (ja) | 2014-11-06 | 2022-08-19 | 抗プロ／潜在型－ミオスタチン抗体およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020127430A JP2020127430A (ja) | 2020-08-27 |
| JP2020127430A5 true JP2020127430A5 (enExample) | 2021-05-13 |
Family
ID=55909861
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523975A Active JP6706617B2 (ja) | 2014-11-06 | 2015-11-06 | 抗プロ／潜在型−ミオスタチン抗体およびその使用 |
| JP2020085618A Withdrawn JP2020127430A (ja) | 2014-11-06 | 2020-05-15 | 抗プロ／潜在型−ミオスタチン抗体およびその使用 |
| JP2022130847A Pending JP2022166238A (ja) | 2014-11-06 | 2022-08-19 | 抗プロ／潜在型－ミオスタチン抗体およびその使用 |
| JP2024077058A Pending JP2024109663A (ja) | 2014-11-06 | 2024-05-10 | 抗プロ／潜在型－ミオスタチン抗体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523975A Active JP6706617B2 (ja) | 2014-11-06 | 2015-11-06 | 抗プロ／潜在型−ミオスタチン抗体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130847A Pending JP2022166238A (ja) | 2014-11-06 | 2022-08-19 | 抗プロ／潜在型－ミオスタチン抗体およびその使用 |
| JP2024077058A Pending JP2024109663A (ja) | 2014-11-06 | 2024-05-10 | 抗プロ／潜在型－ミオスタチン抗体およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10307480B2 (enExample) |
| EP (1) | EP3215175A4 (enExample) |
| JP (4) | JP6706617B2 (enExample) |
| AU (3) | AU2015342936B2 (enExample) |
| CA (1) | CA3005158A1 (enExample) |
| HK (1) | HK1243940A1 (enExample) |
| WO (1) | WO2016073853A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| EP2275443B1 (en) | 2008-04-11 | 2015-12-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| TWI654204B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| WO2013125667A1 (ja) | 2012-02-24 | 2013-08-29 | 中外製薬株式会社 | FcγRIIBを介して抗原の消失を促進する抗原結合分子 |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| SG11201500873XA (en) | 2012-08-24 | 2015-04-29 | Chugai Pharmaceutical Co Ltd | Fcgriib-specific fc region variant |
| TWI636062B (zh) | 2013-04-02 | 2018-09-21 | 中外製藥股份有限公司 | Fc region variant |
| HUE052232T2 (hu) | 2013-05-06 | 2021-04-28 | Scholar Rock Inc | Készítmények és eljárások növekedési faktor modulálására |
| US10307480B2 (en) | 2014-11-06 | 2019-06-04 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| NZ730607A (en) | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| SG11201706583PA (en) | 2015-02-19 | 2017-09-28 | Compugen Ltd | Anti-pvrig antibodies and methods of use |
| PT3922645T (pt) * | 2015-09-15 | 2025-05-29 | Scholar Rock Inc | ¿anticorpos anti-pró-miostatina/miostatina latente e suas utilizações |
| EP3390443A4 (en) * | 2015-12-18 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| CN115814077A (zh) | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| KR20210082548A (ko) * | 2016-06-13 | 2021-07-05 | 스칼러 락, 인크. | 미오스타틴 억제제의 용도 및 조합 요법 |
| MX2018014375A (es) * | 2016-06-17 | 2019-04-22 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina y metodos de uso. |
| BR112019001902A2 (pt) | 2016-08-05 | 2019-07-09 | Chugai Seiyaku Kabushiki Kaisha | composição para profilaxia ou tratamento de doenças relacionadas à il-8 |
| SG11201901077RA (en) | 2016-08-17 | 2019-03-28 | Compugen Ltd | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof |
| US11155611B2 (en) * | 2017-01-06 | 2021-10-26 | Scholar Rock, Inc. | Compositions and methods for making and using anti-myostatin antibodies |
| PT3565592T (pt) | 2017-01-06 | 2023-05-31 | Scholar Rock Inc | Tratamento de doenças metabólicas através da inibição da ativação da miostatina |
| HRP20212034T1 (hr) | 2018-07-11 | 2022-04-01 | Scholar Rock, Inc. | Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe |
| US12252531B2 (en) | 2018-07-11 | 2025-03-18 | Scholar Rock, Inc. | Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitors |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| JP2024524159A (ja) | 2021-06-23 | 2024-07-05 | スカラー ロック インコーポレイテッド | 代謝障害の治療における使用のためのｇｌｐ－１経路活性化剤と組み合わせたミオスタチン経路阻害剤 |
| WO2023079430A1 (en) * | 2021-11-02 | 2023-05-11 | Pfizer Inc. | Methods of treating mitochondrial myopathies using anti-gdf15 antibodies |
| CN114891101B (zh) * | 2021-12-02 | 2023-06-16 | 吉林省农业科学院 | 一种牛肌肉生长抑制素蛋白单克隆抗体及其应用 |
| AU2023413166A1 (en) | 2022-12-22 | 2025-07-03 | Scholar Rock, Inc. | Selective and potent inhibitory antibodies of myostatin activation |
| WO2024187051A1 (en) | 2023-03-07 | 2024-09-12 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
| WO2025240343A1 (en) | 2024-05-13 | 2025-11-20 | Scholar Rock, Inc. | Tgf-beta inhibitors for treating cancer |
| WO2025245160A1 (en) | 2024-05-21 | 2025-11-27 | Scholar Rock, Inc. | Myostatin-selective inhibitors for treating metabolic disorders |
| WO2026008041A1 (zh) * | 2024-07-04 | 2026-01-08 | 江苏恒瑞医药股份有限公司 | 特异性结合潜伏肌生长抑制素的抗原结合分子及其医药用途 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7393682B1 (en) * | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| ES2201076T3 (es) | 1993-03-19 | 2004-03-16 | The Johns Hopkins University School Of Medicine | Factor-8 de diferenciacion del crecimiento. |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| US20030167492A1 (en) | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
| WO1996001845A1 (en) | 1994-07-08 | 1996-01-25 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-11 |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| FR2804102B1 (fr) | 2000-01-26 | 2002-08-16 | Rhodia Terres Rares | Dispersion colloidale aqueuse d'un compose de cerium et d'au moins un autre element choisi parmi les terres rares, des metaux de transition, l'aluminium, le gallium et le zirconium, procede de preparation et utilisation |
| WO2001055086A1 (en) | 2000-01-28 | 2001-08-02 | Novo Nordisk A/S | Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| AU2011244851A1 (en) * | 2000-07-27 | 2011-11-24 | The John Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| ATE364632T1 (de) | 2001-10-05 | 2007-07-15 | Affimed Therapeutics Ag | Antikörper menschlichen ursprungs zur hemmung der thrombozytenaggregation |
| US8455627B2 (en) | 2001-10-05 | 2013-06-04 | Affimed Therapeutics, Ag | Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa |
| PL218992B1 (pl) | 2002-07-19 | 2015-02-27 | Abbott Biotech Ltd | Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ |
| EP1578928B1 (en) | 2002-09-16 | 2010-03-17 | The Johns Hopkins University | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| ATE472556T1 (de) | 2002-12-02 | 2010-07-15 | Amgen Fremont Inc | Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen |
| KR20110086881A (ko) | 2002-12-20 | 2011-08-01 | 암겐 인코포레이티드 | 미오스타틴을 저해하는 결합제 |
| CN1902221A (zh) | 2003-12-31 | 2007-01-24 | 先灵-普劳有限公司 | 基于中和表位的生长增强疫苗 |
| US7456149B2 (en) | 2004-03-02 | 2008-11-25 | Acceleron Pharma, Inc. | ALK7 and myostatin inhibitors and uses thereof |
| US20070178095A1 (en) | 2004-03-23 | 2007-08-02 | Eli Lilly And Company | Anti-myostatin antibodies |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US7316998B2 (en) | 2004-05-27 | 2008-01-08 | Acceleron Pharma Inc. | Cerberus/Coco derivatives and uses thereof |
| JP2008515774A (ja) | 2004-08-03 | 2008-05-15 | ダイアックス コーポレイション | ｈＫ１結合タンパク質 |
| EP1851245B1 (en) | 2005-01-26 | 2012-10-10 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| US20060216279A1 (en) | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
| EP1877075A4 (en) | 2005-04-25 | 2008-07-30 | Pfizer | ANTIBODY TO MYOSTATIN |
| PL2407486T3 (pl) | 2005-08-19 | 2018-05-30 | Wyeth Llc | Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8 |
| ES2533464T3 (es) | 2005-10-06 | 2015-04-10 | Eli Lilly And Company | Anticuerpos anti-miostatina |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| WO2007061995A2 (en) | 2005-11-21 | 2007-05-31 | Novartis Ag | Biomarkers for statin-induced myopathy or rhabdomyolysis |
| US8097596B2 (en) | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
| CA2693378C (en) * | 2006-08-03 | 2020-04-14 | Myostin Therapeutics Pty Ltd | Myostatin antagonists |
| PL2066695T3 (pl) * | 2006-09-05 | 2013-08-30 | Lilly Co Eli | Przeciwciała przeciwko miostatynie |
| ES2569365T3 (es) | 2006-11-29 | 2016-05-10 | Nationwide Children's Hospital | Inhibición de miostatina para la potenciación de músculo y/o la mejora de la función muscular |
| KR101531722B1 (ko) | 2007-03-30 | 2015-06-25 | 메르크 파텐트 게엠베하 | 음성 광학 분산도를 갖는 복굴절층 |
| JP2010529024A (ja) * | 2007-06-01 | 2010-08-26 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｃｒｉｐｔｏ結合分子 |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| EP2300469B1 (en) * | 2008-05-13 | 2015-06-24 | Novartis AG | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
| AR074777A1 (es) * | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | Proteinas de union a antigeno |
| US8952130B2 (en) | 2009-02-24 | 2015-02-10 | The Salk Institute For Biological Studies | Designer ligands of TGF-β superfamily |
| US20120022057A1 (en) * | 2009-03-18 | 2012-01-26 | Schering Corporation | Bicyclic compounds as inhibitors of diacyglycerol acyltransferase |
| CA2993053A1 (en) | 2009-04-27 | 2010-11-04 | Novartis Ag | Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth |
| JP5912078B2 (ja) | 2009-06-08 | 2016-04-27 | アクセルロン ファーマ， インコーポレイテッド | 熱発生性脂肪細胞を増加させるための方法 |
| US8945511B2 (en) | 2009-06-25 | 2015-02-03 | Paul Weinberger | Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3 |
| WO2011040823A1 (en) | 2009-10-01 | 2011-04-07 | Covita Limited | Synthetic myostatin peptide antagonists |
| WO2011110642A2 (en) | 2010-03-10 | 2011-09-15 | Genmab A/S | Monoclonal antibodies against c-met |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| CA2808382A1 (en) | 2010-08-16 | 2012-02-23 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
| US9700619B2 (en) | 2011-11-11 | 2017-07-11 | Duke University | Combination drug therapy for the treatment of solid tumors |
| JP6177249B2 (ja) * | 2011-11-14 | 2017-08-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法 |
| US20130178454A1 (en) | 2011-11-17 | 2013-07-11 | Shalender Bhasin | Combination of testosterone and ornithine decarboxylase (odc) inhibitors |
| WO2013148284A1 (en) | 2012-03-29 | 2013-10-03 | Genentech, Inc. | Antibodies that bind to a pcsk9 cleavage site and methods of use |
| WO2013165972A2 (en) | 2012-04-30 | 2013-11-07 | Cell Signaling Technology, Inc. | Anti-hepatitis b virus antibodies and use thereof |
| MY177331A (en) | 2012-06-15 | 2020-09-12 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
| US20150284455A1 (en) * | 2012-11-06 | 2015-10-08 | Scholar Rock, Inc. | Compositions and methods for modulating cell signaling |
| HUE052232T2 (hu) | 2013-05-06 | 2021-04-28 | Scholar Rock Inc | Készítmények és eljárások növekedési faktor modulálására |
| EP2853898B1 (en) | 2013-09-27 | 2017-01-04 | Medizinische Hochschule Hannover | Analysis of myostatin in serum |
| CA2929574A1 (en) | 2013-11-11 | 2015-05-14 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety |
| WO2015195094A1 (en) | 2014-06-17 | 2015-12-23 | Ember Therapeutics, Inc. | Anti-activin and nati-myostatin antibodies and methods of using the same |
| US10307480B2 (en) | 2014-11-06 | 2019-06-04 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| WO2016073879A2 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related antibodies and uses thereof |
| NZ730607A (en) * | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| WO2016168613A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| PT3922645T (pt) | 2015-09-15 | 2025-05-29 | Scholar Rock Inc | ¿anticorpos anti-pró-miostatina/miostatina latente e suas utilizações |
| CN115814077A (zh) | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| KR20210082548A (ko) | 2016-06-13 | 2021-07-05 | 스칼러 락, 인크. | 미오스타틴 억제제의 용도 및 조합 요법 |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| US11155611B2 (en) | 2017-01-06 | 2021-10-26 | Scholar Rock, Inc. | Compositions and methods for making and using anti-myostatin antibodies |
-
2015
- 2015-11-06 US US15/524,651 patent/US10307480B2/en active Active
- 2015-11-06 JP JP2017523975A patent/JP6706617B2/ja active Active
- 2015-11-06 CA CA3005158A patent/CA3005158A1/en active Pending
- 2015-11-06 AU AU2015342936A patent/AU2015342936B2/en active Active
- 2015-11-06 WO PCT/US2015/059468 patent/WO2016073853A1/en not_active Ceased
- 2015-11-06 HK HK18103508.9A patent/HK1243940A1/zh unknown
- 2015-11-06 EP EP15857125.7A patent/EP3215175A4/en active Pending
-
2019
- 2019-04-04 US US16/374,854 patent/US11135291B2/en active Active
-
2020
- 2020-05-15 JP JP2020085618A patent/JP2020127430A/ja not_active Withdrawn
- 2020-12-22 AU AU2020294193A patent/AU2020294193B2/en active Active
-
2021
- 2021-09-03 US US17/446,897 patent/US11925683B2/en active Active
-
2022
- 2022-08-19 JP JP2022130847A patent/JP2022166238A/ja active Pending
-
2024
- 2024-02-02 US US18/431,294 patent/US20240374718A1/en active Pending
- 2024-05-10 JP JP2024077058A patent/JP2024109663A/ja active Pending
- 2024-05-14 AU AU2024203178A patent/AU2024203178A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022166238A5 (enExample) | ||
| KR101998535B1 (ko) | Tl1a에 특이적으로 결합하는 항체 | |
| AU2018263935B2 (en) | Antibodies recognizing tau | |
| JP7481726B2 (ja) | タウ認識抗体 | |
| JP2025016349A5 (enExample) | ||
| RU2429245C2 (ru) | Иммуноглобулины | |
| US11827701B2 (en) | IL-6 binding molecules | |
| JP7630834B2 (ja) | タウ認識抗体 | |
| JP2019527194A5 (enExample) | ||
| US20150183877A1 (en) | Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains | |
| JP2025063136A (ja) | タウ認識抗体 | |
| JP2012531902A (ja) | ポリペプチドおよび治療の方法 | |
| CN101983208A (zh) | 胰高血糖素受体拮抗剂 | |
| CN112105639B (zh) | 抗PHF-tau抗体及其用途 | |
| JP2017536354A5 (enExample) | ||
| US12577298B2 (en) | Anti-IL-5 antibodies | |
| JP2020521504A (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| JP2024515536A5 (enExample) | ||
| CN109071643B (zh) | 亲和力改造的血清蛋白载体结合结构域 | |
| CN113677701A (zh) | 产生亲合结合多特异性抗体的方法 | |
| US20230174672A1 (en) | Protein s antibodies, methods of making and uses thereof | |
| CA3242070A1 (en) | Antibodies recognizing sortilin | |
| JP2018203735A5 (enExample) | ||
| US11981727B2 (en) | Monospecific and bispecific antibodies and antigen binding fragments thereof | |
| WO2023044280A1 (en) | Anti-il-1-beta antibodies |